Pfizer to merge generics unit with Mylan; seeks to sharpen cancer focus

Drugmaker Pfizer Inc has agreed to spin off its generic drugs business and combine it with Mylan , a move that leaves Pfizer with more profitable innovative drugs, including cancer drug Ibrance and pneumonia vaccine Prevnar.